Non-cash impairment of SEK 4.3 billion in the fourth quarter 2023, relating to the impairment of goodwill attributed to the acquisition of Igenomix in 2021. Igenomix, now known as the business area Genetic Services, remains a core part of the new corporate strategy for the Vitrolife…